Mitsubishi Chemical Group Corporation [4188.T]
TOKYO, May 13 (Pulse News Wire) – Mitsubishi Chemical Group Corporation (4188.T) reported lower-than-expected core operating profit for its fiscal year ending March 31, 2026. The company’s core operating profit came in at ¥323 billion compared to the previously forecasted ¥650 billion.
The discrepancy was primarily due to impairment losses recorded in the Specialty Materials and Basic Materials & Polymers segments. Specifically, Mitsubishi Chemical recognized impairment losses related to Mitsubishi Rayon's Soviet Anooru Seizou Setsubi and its own ethylene oxide and Athylen Glykol Rui Seizou Setsubi assets. As a result, profits fell below initial projections across all stages post-core operating income. Additionally, the company transferred its entire stake and associated assets of Nichion Pharmaceutical Co., Ltd. through absorption-type share exchange at the regular shareholders' meeting held on June 25, 2025.
This transaction led to the classification of Nichion Pharmaceutical and its subsidiaries’ operations as discontinued businesses since July 1, 2025. Notably, Nichion Pharmaceutical changed its name to Nichion Holdings Co., Ltd. on December 01, 2025. In light of the significant impairment loss, the company’s chairman and president, Mr. Makoto Tsukimoto, along with executives from Mitsubishi Film & Plastics Corporation, offered to voluntarily return their monthly compensation.
Mitsubishi Chemical accepted these offers, which cover a six-month period.
🟢 Confidence: High AI-translated content.